Pharmaceutical Technology

MARCH 2, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate is an engineered B-cell modulator. The company offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics.

Protein 100

Protein Engineer Drugs Clinical Trials 100

Pharmaceutical Technology

MARCH 23, 2023

Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics. Adcetris is currently active in multiple clinical trials, including the ECHELON-3 Phase lll study for patients with relapsed or refractory diffuse large B-cell lymphoma.

Licensing 147

Licensing Licensing Sales Trials 147

XTalks

AUGUST 8, 2024

Tecelra is the first cell therapy engineered for a solid tumor cancer in the US, offering a new option for patients with specific genetic markers who have previously undergone chemotherapy. Tecelra works by using the patient’s own immune system to target tumors expressing the melanoma-associated antigen A4 (MAGE-A4) protein on cancer cells.

Engineer 52

Engineer Clinical Trials Clinical Trials FDA Approval 52

The Pharma Data

MARCH 23, 2022

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. The researchers discovered that Ebola virus polymerase hijacks a cellular protein called GSPT1. To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase.

Protein 52

Protein Genome Genomics Research 52

Scienmag

APRIL 12, 2021

Credit: POSTECH Blood vessels deliver nutrients and oxygen to each organ in our body. They are difficult to completely restore to their original conditions once damaged by myocardial infarction or severe ischemic diseases. This is because various angiogenic growth factors must be applied sequentially in order to restore the vascular structure.

Protein 83

Protein Research Clinical Trials Clinical Trials 83

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Most train the immune system to recognize the RBD, a peptide that is the portion of the SARS-CoV-2 spike protein that binds to the ACE-2 receptor on host cell surfaces. bioRxiv [Preprint].

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. Chief Executive Officer at Arvinas.

Protein 52

Protein Development HR Hormones 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

pharmaphorum

NOVEMBER 29, 2022

Number of on-going clinical trials: 14. That is where the company believes they have discovered a potent IO therapy with NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7. Locations: 3 (US HQ, Korea office, Korea R&D center). Number of employees: 90+ (as of Oct. Creation: Jan. Infectious Diseases.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Engineer 105

XTalks

NOVEMBER 23, 2020

The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

pharmaphorum

APRIL 8, 2022

The Dublin-based pharma is paying $15 million upfront for global rights to Werewolf’s WTX-613, a prodrug of the cytokine interferon alfa-2b, which is still back n preclinical development and due to start its first clinical trials next year. Image by Lukas Bieri from Pixabay .

Drugs 105

Drugs Immune Response Licensing Licensing 105

XTalks

SEPTEMBER 21, 2023

“HIV continues to be a major global public health challenge with no approved vaccines despite decades of research efforts,” said Carey Hwang, Vir’s Senior Vice President, Clinical Research, Head of Chronic Infection, in the company’s press release. mRNA, 2) BG505 MD39.3 gp151 mRNA and 3) BG505 MD39.3 gp151 CD4KO mRNA.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

AUGUST 19, 2022

Beta thalassemia is a rare inherited blood disorder caused by mutations in the beta-globin gene leading to a reduced amount, or complete absence, of the beta chains of the oxygen-carrying hemoglobin protein in red blood cells. XTALKS WEBINAR: How Agile Clinical Trials Unlock Universal Access to Rare Disease Research.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

pharmaphorum

JANUARY 3, 2023

SPK-9001 is a novel, investigation vector containing a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity human coagulation FIX gene. The clinical trial participants will be evaluated as part of a long-term study over 15 years.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. “Our minibinders sit on top of the spike protein like a tripod and block all three.

Antibody 52

Antibody Protein Engineer Research 52

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. Novavax expects to begin its pivotal Phase 3 clinical trial in the United States and Mexico by the end of November. and globally.”.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 24, 2023

cell surface protein, including gastric cancers. Currently, the ADC is being assessed in a Phase I clinical trial to treat Claudin 18.2-positive According to the trial’s preliminary data, CMG901 was found to have a favourable safety and tolerability profile and encourage anti-tumour efficacy across the tested dose levels.

Antibody 130

Antibody Development Engineer Clinical Trials 130

Bioengineer

JULY 20, 2021

Surgical scars treated with a molecule called alphaCT1 showed a long-term improvement in appearance when compared to control scars, according to multicenter, controlled Phase II clinical trials – a finding that could help surgeons improve patient outcomes. to bring alphaCT1 to market. Original Source. https:/ / vtx.

Scientist 52

Scientist Engineer Research Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. pivotal Phase 3 trial update. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Roots Analysis

DECEMBER 9, 2021

The anti-HER2 therapies target the HER2 receptor proteins present on the surface of tumor cells, inhibiting the HER2 receptors from receiving signals in order to terminate the cellular growth. These therapies can be used as a monotherapy or in combination with other therapeutic modalities, such as chemotherapy, surgery or radiation therapy.

Marketing 52

Marketing Development Gene Protein 52

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up. ” The post CureVac and GSK try again with COVID-19 vaccine appeared first on.

Vaccination 64

Vaccination Vaccine Protein Antibody 64

Bioengineer

JULY 23, 2021

Credit: Texas A&M Engineering. The team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station. “For the first time, we identified a crucial interaction between platelets and the tumor via their surface proteins,” Jain said. ” ###. Original Source.

Engineer 52

Engineer Gene Editing Clinical Trials Clinical Trials 52

Roots Analysis

DECEMBER 13, 2021

According to research study, 69% of participant were found to take part more likely in clinical trials, if they are able to provide self-collected sample (at-home blood collection). However, in recent years, the methods for blood collection are evolving at a rapid pace. Our Social Media Platform.

Engineer 52

Engineer Clinical Trials Clinical Trials Protein 52

XTalks

JANUARY 8, 2024

The FDA’s endorsement stems from results obtained from the company’s Phase III NefIgArd clinical trial. This accumulation triggers inflammation and damages kidney tissues, leading to the leakage of blood and protein into the urine. IgAN, a rare kidney disorder, is marked by the accumulation of IgA deposits within the kidneys.

FDA Approval 64

FDA Approval Clinical Trials Clinical Trials Nurses 64

pharmaphorum

MARCH 28, 2022

AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to assemble a fully funded start-up company.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

The Pharma Data

DECEMBER 31, 2020

Prior to joining Taysha, Gara served as vice president of Pharmaceutical Engineering at Sarepta, where he led and managed manufacturing operations for all gene therapy products. Before Sarepta, he served as vice president of Technical Operations and Engineering at AveXis, a Novartis company.

Gene Therapy 52

Gene Therapy Engineer Gene Research Analyst 52

XTalks

MAY 25, 2022

The hydroxyapatite was engineered to be a specific size and crystallinity which can help deliver the bone void filler in the form of an injection and allows for a slow resorption rate as well. -calcium sulfate hemihydrate (CaS) and hydroxyapatite (HA) in a ratio of 60 weight percent and 40 weight percent, respectively.

Filler 98

Filler Production Marketing Sales 98

Delveinsight

AUGUST 11, 2020

Evrysdi is orally administered and was evaluated in a broad clinical trial program with patients range from birth to 60 years old, including difficult-to-treat populations whose disease had progressed. Roche’s Gut Disease Drug, Etrolizumab Presents Muddled Results in Ulcerative Colitis Trials .

Clinical Trials 52

Clinical Trials Clinical Trials Trials Protein 52

The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

JANUARY 13, 2021

HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. Dose escalation for HPN217 in the Phase 1/2 clinical trial is progressing rapidly. NYSE: ABBV).

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

pharmaphorum

APRIL 1, 2021

For example, you can simulate what would happen if you inhibited thousands of different proteins in thousands of different cell models.”. But with a host of well-educated doctors, biologists, engineers and software developers in the country, this gap has been filled by a strong digital health ecosystem. So what do they do?

Bioinformatics 123

Bioinformatics Drugs Development Scientist 123

WCG Clinical

NOVEMBER 17, 2023

This change expanded the definition of HGT research to include research using nucleic acids that are able to replicate, be transcribed, translated into protein, and/or integrate into the host genome. Since then, however, certain genetic engineering technologies (e.g.,

Genome 52

Genome Genomics Gene Editing Genetic Engineering 52

The Pharma Data

DECEMBER 15, 2020

Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 NEW HAVEN, Conn., Forward-Looking Statements.

Protein 40

Protein Containment Engineer Sales 40

XTalks

JUNE 4, 2024

The advent of cell therapies, particularly those harnessing advanced cell engineering techniques initially developed for cancer treatment, offers a new frontier in the management, and potential cure, of autoimmune conditions. This makes it difficult to blind and use a placebo group.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Antibody 52

The Pharma Data

OCTOBER 19, 2020

With over 300 active clinical trials, Winship researchers are dedicated to taking new cancer treatments from bench to bedside. cancer centers selected as a Lead Academic Participating Site for the NCI’s National Clinical Trials Network (NCTN). Winship is one of 32 U.S.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

XTalks

MAY 24, 2024

” XTALKS WEBINAR: AI-based Antibody Therapeutics Developability Assessment and Its Engineering Live and On-Demand: Friday, June 21, 2024, at 10am EDT (4pm CEST/EU-Central) Register for this webinar today to learn how AI can be used to improve developability screening of antibody therapeutics and optimization of antibody candidates.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52